Related Experiment Video
Updated: May 6, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
[Potential and perspective of genetic testing in Renaissance of laboratory medicine]
1Department of Molecular and Laboratory Medicine, Mie University Graduate School of Medicine, Tsu 514-8507, Japan. nobori@clin.medic.mie-u.ac.jp
Abstract:
Among molecular genetic tests, tests for genomic biomarkers are increasingly performed in order to decide the right drug for the right patient at the right time. These genetic tests, including pharmacogenomics (PGx) tests, are essential for personalized medicine. Companion diagnostics (CDx) will be co-developed from the early stage of drug development and used for patient stratification in Phases II/III of clinical trials. The strategic change in development from blockbuster drugs to molecularly targeted drugs will enhance the clinical application of genetic tests, including CDx and PGx. The genetic tests utilized for making treatment decisions have the potential to regenerate laboratory medicine.
Related Concept Videos
Modern Molecular Taxonomy
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
Pharmacogenomics: Identification of New Drug Targets
Genomics
Automated Microbial Diagnostics
Pharmacogenetics and Pharmacogenomics: Overview

